Particulate Findings in B. Braun IV Bags Prompt Nationwide Recall

B. Braun Medical Inc. is recalling two lots of Lactated Ringer's Injection, E7500, 1L, after complaint investigations identified particulate matter in solution, exposing a breakdown in particulate control within its sterile IV manufacturing process. The recall, conducted to the hospital and healthcare facility level, carries implications that extend well beyond two affected lots: QA teams across sterile injectables manufacturing should treat this as a prompt to audit their own complaint investigation SOPs and particulate identification workflows.

The particles identified through complaint investigations were characterized as cellulose and stearates, with extremely low levels of inorganic materials including copper. That combination points investigators toward potential contamination pathways involving container components, processing aids, or equipment wear rather than a raw material or environmental source alone. The two recalled lots, E3J4P756 and E3J4S843, both carry NDC 0264-7750-07 and an expiration date of 31 May 2027. Distribution was nationwide to distributors, hospitals, and healthcare facilities.

The clinical risk profile for this recall is serious. Per B. Braun's own announcement, particulate matter infused intravenously carries the potential for pulmonary emboli, vascular occlusion, phlebitis, immune activation, organ dysfunction, and hemolysis. The product is indicated for both adult and pediatric patients, broadening the at-risk population. B. Braun has reported no adverse events to date, but the company's recall notice explicitly acknowledges the potential for permanent impairment or death if contaminated product reaches a patient's circulatory system.

For QA directors and plant heads, the particulate characterization data here illustrates why complaint investigations under 21 CFR Part 211 and ICH Q10 must include rigorous particle identification, not simply visual confirmation of a defect. Cellulose and stearate findings require traceability back through bill of materials, equipment contact surfaces, and closure systems. Container closure integrity evaluation should be part of any root cause investigation where particulate composition suggests an internal rather than external contamination source.

B. Braun is notifying distributors and customers by mail and has arranged for product return via an Urgent Pharmaceutical Recall Acknowledgement form. Facilities holding affected lots should cease use immediately. Questions can be directed to B. Braun's Recalls Department at 844-903-6417 or recalls@bbraunusa.com. This recall is being conducted with the knowledge of the FDA. Adverse events may be reported through the FDA MedWatch program at fda.gov/medwatch/report.htm.